APOA1 and metabolic dysfunction-associated steatotic liver disease: Fernando Bril focused on MASLD patients with fibrosis and analyzed LCAT mass on the basis of His-apoAI binding proteomics, and Janac et al. focused on lipid disorders in MASLD patients and measured the decrease in endogenous substrates (plasma FC) to indicate LCAT activity.